These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 26073262

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review.
    Moossdorff-Steinhauser HF, Berghmans B.
    Neurourol Urodyn; 2013 Mar; 32(3):206-14. PubMed ID: 22907807
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA.
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
    Chen HW, Bercik RS, Werner EF, Thung SF.
    J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Patient-reported outcomes in the setting of a randomized control trial on the efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome.
    Ramírez-García I, Kauffmann S, Blanco-Ratto L, Carralero-Martínez A, Sánchez E.
    Neurourol Urodyn; 2021 Jan; 40(1):295-302. PubMed ID: 33118624
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder.
    Salatzki J, Liechti MD, Spanudakis E, Gonzales G, Baldwin J, Haslam C, Pakzad M, Panicker JN.
    BJU Int; 2019 May; 123(5A):E20-E28. PubMed ID: 30552801
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months.
    Vecchioli-Scaldazza C, Morosetti C.
    Int Braz J Urol; 2018 May; 44(1):102-108. PubMed ID: 29064651
    [Abstract] [Full Text] [Related]

  • 18. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.
    Peters KM, Carrico DJ, MacDiarmid SA, Wooldridge LS, Khan AU, McCoy CE, Franco N, Bennett JB.
    Neurourol Urodyn; 2013 Jan; 32(1):24-9. PubMed ID: 22674493
    [Abstract] [Full Text] [Related]

  • 19. Non-inferior and more feasible transcutaneous tibial nerve stimulation in treating overactive bladder: A systematic review and meta-analysis.
    Alomari MS, Abdulhamid AS, Ghaddaf AA, Alshareef KM, Haneef AK, AlQuhaibi MS, Banjar RA.
    Int J Urol; 2022 Oct; 29(10):1170-1180. PubMed ID: 35711082
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.